|
1
|
Schaefer A, Stephan C, Busch J, Yousef GM
and Jung K: Diagnostic, prognostic and therapeutic implications of
microRNAs in urologic tumors. Nat Rev Urol. 7:286–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huntzinger E and Izaurralde E: Gene
silencing by microRNAs: Contributions of translational repression
and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: T arget recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
6
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guil S and Esteller M: DNA methylomes
histone codes and miRNAs: Tying it all together. Int J Biochem Cell
Biol. 41:87–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ridge CA, Pua BB and Madoff DC:
Epidemiology and staging of renal cell carcinoma. Semin Intervent
Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tavani A: LaV ecchia C: Epidemiology of
renal-cell carcinoma. J Nephrol. 10:93–106. 1997.PubMed/NCBI
|
|
12
|
National Cancer Institute: Surveillance,
Epidemiology, and End Results Program. SEER Stat Fact Sheets:
Kidney and Renal Pelvis Cancer. http://seer.cancer.gov/statfacts/html/kidrp.htmlAccessed.
March 30–2013
|
|
13
|
Patel C, Ahmed A and Ellsworth P: Renal
cell carcinoma, A reappraisal. Urol Nurs. 32:182–190.
2012.PubMed/NCBI
|
|
14
|
Lam JS, Leppert JT, Figlin RA and
Belldegrun AS: Role of molecular markers in the diagnosis and
therapy of renal cell carcinoma. Urology 66 (Suppl). 1–9. 2005.
View Article : Google Scholar
|
|
15
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dias F, Teixeira AL, Santos JI, Gomes M,
Nogueira A, Assis J and Medeiros R: Renal cell carcinoma
development and miRNAs, A possible link to the EGFR pathway.
Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al-Ali BM, Ress AL, Gerger A and Pichler
M: MicroRNAs in renal cell carcinoma, Implications for
pathogenesis, diagnosis, prognosis and therapy. Anticancer Res.
32:3727–3732. 2012.PubMed/NCBI
|
|
18
|
Liu H, Brannon AR, Reddy AR, Alexe G,
Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yi Z, Fu Y, Zhao S, Zhang X and Ma C:
Differential expression of miRNA patterns in renal cell carcinoma
and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM,
Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a
4-microRNA signature for clear cell renal cell carcinoma metastasis
and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Isobe T, Hisamori S, Hogan DJ, Zabala M,
Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS,
et al: miR-142 regulates the tumorigenicity of human breast cancer
stem cells through the canonical WNT signaling pathway. eLife.
3:019772014. View Article : Google Scholar
|
|
23
|
Colamaio M, Puca F, Ragozzino E, Gemei M,
Decaussin-Petrucci M, Aiello C, Bastos AU, Federico A, Chiappetta
G, Del Vecchio L, et al: miR-142-3p down-regulation contributes to
thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J
Clin Endocrinol Metab. 100:E59–E69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chai S, Tong M, Ng KY, Kwan PS, Chan YP,
Fung TM, Lee TK, Wong N, Xie D, Yuan YF, et al: Regulatory role of
miR-142-3p on the functional hepatic cancer stem cell marker CD133.
Oncotarget. 5:5725–5735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han J, Yu J and Ling Z: Screening of
specific miRNA in early gastric cancer. Zhonghua Wei Chang Wai Ke
Za Zhi. 17:175–179. 2014.(In Chinese). PubMed/NCBI
|
|
26
|
Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J
and Zhang HT: MiR-142-3p represses TGF-β-induced growth inhibition
through repression of TGFβR1 in non-small cell lung cancer. FASEB
J. 28:2696–2704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dou L, Li J, Zheng D, Li Y, Gao X, Xu C,
Gao L, Wang L and Yu L: MicroRNA-142-3p inhibits cell proliferation
in human acute lymphoblastic leukemia by targeting the MLL-AF4
oncogene. Mol Biol Rep. 40:6811–6819. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang
H, Hong M, Jiang T, Jiang Q, Lu J, et al: An oncogenic role of
miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by
targeting glucocorticoid receptor-α and cAMP/PKA pathways.
Leukemia. 26:769–777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanaan Z, Roberts H, Eichenberger MR,
Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and
Galandiuk S: A plasma microRNA panel for detection of colorectal
adenomas, A step toward more precise screening for colorectal
cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanaka K, Kondo K, Kitajima K, Muraoka M,
Nozawa A and Hara T: Tumor-suppressive function of protein-tyrosine
phosphatase non-receptor type 23 in testicular germ cell tumors is
lost upon overexpression of miR142-3p microRNA. J Biol Chem.
288:23990–23999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF,
Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM and Xu LY: miR-142-3p as
a potential prognostic biomarker for esophageal squamous cell
carcinoma. J Surg Oncol. 105:175–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hui AB, Lenarduzzi M, Krushel T, Waldron
L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O'Sullivan B,
Waldron J, et al: Comprehensive microRNA profiling for head and
neck squamous cell carcinomas. Clin Cancer Res. 16:1129–1139. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Edge SB, Byrd DR, Compton CC, et al: AJCC
Cancer Staging Manual (7th). New York, NY, USA: Springer Verlag.
547–560. 2009.
|
|
35
|
Rydzanicz M, Wrzesiński T, Bluyssen HA and
Wesoły J: Genomics and epigenomics of clear cell renal cell
carcinoma. Recent developments and potential applications. Cancer
Lett. 341:111–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maher ER: Genomics and epigenomics of
renal cell carcinoma. Semin Cancer Biol. 23:10–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chow TF, Mankaruos M, Scorilas A, Youssef
Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, et
al: The miR-17-92 cluster is over expressed in and has an oncogenic
effect on renal cell carcinoma. J Urol. 183:743–751. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen WW, Zeng Z, Zhu WX and Fu GH:
miR-142-3p functions as a tumor suppressor by targeting CD133,
ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl).
91:989–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chapnik E, Rivkin N, Mildner A, Beck G,
Pasvolsky R, Metzl-Raz E, Birger Y, Amir G, Tirosh I, Porat Z, et
al: miR-142 orchestrates a network of actin cytoskeleton regulators
during megakaryopoiesis. eLife. 3:e019642014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaduthanam S, Gade S, Meister M, Brase JC,
Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann
H, et al: Serum miR-142-3p is associated with early relapse in
operable lung adenocarcinoma patients. Lung Cancer. 80:223–227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z,
Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, et al: miR-29a and
miR-142-3p downregulation and diagnostic implication in human acute
myeloid leukemia. Mol Biol Rep. 39:2713–2722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mascaux C, Laes JF, Anthoine G, Haller A,
Ninane V, Burny A and Sculier JP: Evolution of microRNA expression
during human bronchial squamous carcinogenesis. Eur Respir J.
33:352–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
